Skip to content

Released Nov 8, 2018, after the close

10-Q filed Nov 8, 2018, 39 days after period end · 0001564590-18-028526

Q3 2018 · 10-Q
Revenue$658.00K+10.2% vs Q3 2017+42.1% vs Q2 2018
Net Income-$10.46MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.60N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$10,935,000N/M
Operating Cash Flowderived-$5,514,000N/M
Margins · derived
Operating margin-1661.9%+7.5 pt vs Q3 2017
Net margin-1590.1%+57.4 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016
Revenue$658.00K$597.00K—
Net Income-$10.46M-$9.84M-$6.32M
EPS Diluted-$0.60-$36.02-$23.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR